Research study of an investigational medication for those who are at risk to develop Alzheimer’s Disease.

Study Description

A phase 2, 3.5-year, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of an investigational drug in the treatment of subjects with Prodromal Alzheimer’s Disease.

Length of study: Approximately 3.5 years

Number of office visits: 17 to 23

At no cost, qualified participants receive:

Study-related memory evaluation by a Board-Certified Geriatric Psychiatrist

• Study medication or placebo (inactive substance)
• Diagnostic and laboratory evaluations
• Study-related MRI scan and lumbar puncture
• Reimbursement of up to $2025 for time and travel

Study inclusion/exclusion criteria

This study is only available if the following apply to the potential participant:

• Has significant early memory impairment
• Can easily read and speak English
• Is between 45 and 90 years old
• Is in good general health

[Home] [For Patients] [Studies] [FAQ] [Sponsor Overview] [Contact Us]